

## New Generic Approvals

- **Lifitegrast Ophthalmic Solution 5%**  
Approved: August 4, 2023 - Micro Labs Limited  
Treatment for: Dry Eye Disease
- **Halobetasol Propionate Aerosol Foam 0.05%**  
Approved: August 11, 2023 - Padagis Israel Pharmaceuticals Ltd.  
Treatment for: Plaque Psoriasis
- **Joyeaux Tablets ethinyl estradiol 0.02 mg / levonorgestrel 0.1 mg with ferrous fumarate 75 mg**  
Approved: August 16, 2023 - Xiromed, LLC  
Treatment for: Birth Control
- **Tretinoin Gel (Microsphere) 0.08%**  
Approved: August 22, 2023 - Encube Ethicals Private Limited  
Treatment for: Acne Vulgaris
- **Lisdexamfetamine Dimesylate Capsules 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg**  
Approved: August 25, 2023 - Actavis Elizabeth LLC; Alkem Laboratories Limited; Amneal Pharmaceuticals LLC (excl. 10 mg); Apotex Corp.; Ascent Pharmaceuticals, Inc.; Hikma Pharmaceuticals USA Inc. (excl. 10 mg); Lannett Company, Inc.; Mylan Pharmaceuticals Inc.; Norwich Pharmaceuticals, Inc.; Princeton Pharmaceutical Inc.; Rhodes Pharmaceuticals L.P.; SpecGx LLC; Sun Pharmaceutical Industries, Inc.  
Treatment for: ADHD; Binge Eating Disorder
- **Lisdexamfetamine Dimesylate Chewable Tablets 10 mg, 20 mg, 30 mg, 40 mg, 50 mg and 60 mg**  
Approved: August 25, 2023 - Ascent Pharmaceuticals, Inc.; Sun Pharmaceutical Industries, Inc.; Teva Pharmaceuticals USA, Inc.  
Treatment for: ADHD; Binge Eating Disorder
- **Palbociclib Tablets 75mg, 100 mg and 125 mg**  
Approved: August 28, 2023 - Synthron Pharmaceuticals, Inc.  
Treatment for: Breast Cancer
- **Spironolactone Oral Suspension 25mg/5mL**  
Approved: September 5, 2023 - Amneal Pharmaceuticals LLC  
Treatment for: NYHA Class III-IV Heart Failure and Reduced Ejection Fraction
- **Tofacitinib Citrate Oral Solution 1 mg (base)/ml**  
Approved: September 25, 2023 - Slayback Pharma LLC  
Treatment for: Polyarticular Course Juvenile Idiopathic Arthritis
- **Pazopanib Hydrochloride Tablets 200 mg (base)**  
Approved: October 19, 2023 - Apotex Corp.; Sun Pharmaceutical Industries, Inc.; Teva Pharmaceuticals U SA, Inc.  
Treatment for: Renal Cell Carcinoma; Soft Tissue Sarcoma
- **Teriparatide Injection 600 mcg/2.4 mL (250 mcg/ml)**  
Approved: November 16, 2023 - Apotex Corp.; Teva Pharmaceuticals USA, Inc.  
Treatment for: Osteoporosis
- **Podofilox Topical Gel 0.5%**  
Approved: November 22, 2023 - Padagis US LLC  
Treatment for: Anogenital Warts
- **Bromfenac Sodium Sesquihydrate Ophthalmic Solution 0.07% (free acid)**  
Approved: November 22, 2023 - Lupin Pharmaceuticals, Inc.  
Treatment for: Ocular Inflammation and Pain After Cataract Surgery
- **Nilotinib Hydrochloride Capsules 50mg (base), 150mg (base) and 200mg (base)**  
Approved: January 5, 2024 - Apotex Corp.  
Treatment for: Chronic Myeloid Leukemia

*References: [www.drugs.com](http://www.drugs.com)*

**Information collected and compiled by**

**Md. Akbar Hossain**

ASA University (ASAUB), Shyamoli, Mohammadpur  
Dhaka-1207, Bangladesh